Dermatological Acceptability and Efficacy in Improving Xerosis, Skin Hydration, and Barrier Function

Inclusion criteria

• Male and female participants aged 36 to 65 years.
• Participants presenting moderate to severe xerosis of the lower limbs, corresponding to grades 2 or 3 on the Overall Dry Skin Score (ODS) scale, confirmed by clinical evaluation.
• Participants presenting a stratum corneum hydration index between 35 and 55 arbitrary units (AU), as measured by corneometry on the forearm during the eligibility assessment.
• Participants considered healthy by the investigator, with no medical conditions or use of medications that could pose an undue risk or interfere with the study results.
• Willingness to comply with all study procedures and attend the study site on the scheduled dates and times for assessments.
• Ability to understand the study requirements, provide written informed consent, and sign the Informed Consent Form (ICF).

Exclusion criteria

• Pregnant or breastfeeding women, or women at risk of becoming pregnant during the study, when applicable.
• Use of anti-inflammatory, immunosuppressive, antihistamine, or any other medication that, in the investigator's opinion, may interfere with skin condition assessments or study outcomes.
• Presence of skin marks in the test area that may interfere with clinical or instrumental evaluations of skin reactions, including vascular malformations, scars, excessive hair growth, multiple nevi, or sunburn.
• Presence of active atopic dermatitis, eczema, or other dermatoses that may interfere with evaluation of the test area.
• Active localized or generalized skin diseases and/or lesions in the assessment area that, in the investigator's opinion, may compromise participation in the study.
• Immunosuppression due to medication use or active disease.
• Uncontrolled endocrine disorders.
• Presence of significant vascular alterations in the lower limbs, such as severe venous insufficiency, significant edema, lymphedema, or ulcers that may interfere with study assessments.
• Relevant medical history or current evidence of alcohol or substance abuse.
• Known history of or suspected intolerance to products of the same category.
• Intense sun exposure within 15 days prior to the baseline assessment.
• Aesthetic or dermatological treatments within 4 weeks prior to the baseline assessment.
• Procedures that may temporarily alter skin condition in the test area, such as exfoliation or hair removal, within the timeframe specified by the study protocol.
• Any other condition that, in the investigator's opinion, may pose a risk to the participant, interfere with protocol compliance, or compromise the interpretation of study results.